Skip to main content
Premium Trial:

Request an Annual Quote

Amsterdam Molecular Therapeutics Says AAV-RNAi Approach Inhibits ApoB


Amsterdam Molecular Therapeutics this week announced preclinical data showing that its proprietary siRNA-based technology could be used to inhibit apolipoprotein B and trigger a drop in plasma cholesterol levels in mice.

The agent uses adeno-associated viral vectors to deliver apoB-targeting siRNA sequences that have been incorporated into microRNA scaffolds, according to the company. A single injection of the so-called AAV-miApoB into mice "transduced murine hepatocytes almost entirely and resulted in a reduction of total plasma cholesterol of 60 [to] 80 percent for an 18-week period," it added.

"Successful hepatocyte-specific delivery of microRNA and significant demonstration of gene silencing again illustrates the strength of [the firm's] AAV platform," AMT CEO Jorn Aldag said in a statement.

This "application of our technology may circumvent some of the delivery issues with the RNA approach," he added. "We intend to seek partners to exploit the full AAV technology potential in the RNA field."

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.